Industry NHS data sharing for collaborative product development

Transcription

1 Industry NHS data sharing for collaborative product development

2

3 Changing strategies in clinical evidence gathering: Are randomised, doubleblinded studies to become extinct?

4 The RCT is not extinct, but neither is it the answer to everything The hierarchy of evidence is determined by the purity of answering a scientific question and is medically centric, becoming further away from the patient. The challenge of evidence generation must be about the question that is most relevant, and the drive to improve quality, ultimately giving confidence to individual benefit/risk discussions or how to effectively arrange a new service in complex models.

5 An evidence driven operating model Scientific messages Can I generalise the data? Patient Pathway HCP Formulary Rx Evidence base to position this within a formulary cascade Decision Pathway RWE Clinical Audit Platform Measuring outcomes in Real-Time

6 Every interaction is unique complexity is standard Healthcare interaction Can I generalise the data? Patient Outcome benefit Is this noticeable or relevant? Comorbidities Complex therapeutics Behaviour change

7 The method should be defined by what we measure and what question we have Science Industry and the healthcare system research is driven by necessity (license) and an interest in the scientific (researcher or university) Population Population, healthcare system and patient centric approach is far more undifferentiated and requires a greater variety of methodology Patient

8 Healthcare touch point measurementsultimately all interactions are 1 on 1 The challenge of measurement is one of complexity of infrastructure and not measuring relevant performance outcomes Healthcare Patient Performance Outcome Satisfaction

9 Capitalising on Real World Evidence Interpretation Big Data Real World Meaning

10

11 BIG data is just data with challenges Healthcare systems need to take the lead, make measurement of care standard practice and work in partnership to assess real world effectiveness

12 Industry NHS data sharing for collaborative product development

13 Company profile The challenge of getting the right drug, to the right patient at the right time is becoming increasingly complicated. Our team makes the difference; direct experience of senior leadership in pharmaceuticals and healthcare, a unique payer and HTA perspective, giving focused strategic insights for better and quicker decisions. Unlike other companies, we have unique experience of all customer groups, from politicians to patients, payers to prescribers. Possessing extensive global pharmaceutical company experience, we give confidence when delivering what is customer relevant. Senior leaders work directly for clients, delivering bespoke medical and market access consultancy, offering unique insight at all stages of brand life cycle. The business will allow outsourcing of expertise with the confidence to deliver projects to time and budget. Specialties: Market access solutions, Evidence-based medicine/healthcare, Medical Affairs, HTA, Big Data, policy into practice, expert clinician, NICE technology appraisal committee member, change management, strategic partnerships, payer insights & communication, value based strategy, reimbursement strategy, health service redesign, Key Account Management, pharmaceuticals, launch excellence, UK, Europe and global.

14 Dr David T Williams - Director MBBCh MSc (HEcon and EBM) DCH Dip Ther FRACGP FACRRM 24 years as a qualified physician, with 14 years in the pharmaceutical industry Masters graduate in health economics and Evidence Based Medicine Extensive leadership experience in medical affairs in Europe, as well as being Head of Global HEOR UK and as Head of Global Government Affairs, AstraZeneca Chief Medical Officer of Lifecode Ltd Big Data and Health Economic specialist consultancy Global lead of payer projects and drug launches: Pharmaceutical experience - in neurology, diabetes, biologics, endocrinology, ADHD, gastrointestinal medicine, nephrology, oncology, respiratory medicine, urology, rheumatology, anti-infectives and haematology Experience: UK and Australian clinical practice, University of Western Australia, Boehringer Ingelheim, GSK, Ardana, Prostrakan, AstraZeneca and Shire. In medical, R&D, HEOR and Government Affairs

15